|
| Status |
Public on Feb 09, 2021 |
| Title |
HG2_CM272_R2 |
| Sample type |
RNA |
| |
|
| Source name |
HepG2, hepatocellular carcinoma cell line, ATCC® HB-8065™, treated with CM272
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: HepG2
treatment: CM272 at 400nM during 48 hours
|
| Treatment protocol |
Cells were seeded at a density of 200000 cells / well in 6-well plates. After overnight incubation, cells were treated for 48 h with vehicle alone (0.1% DMSO) or with CM272 at 400nM in culture medium supplemented with 10% FBS (HepG2) or 2% FBS (LX2) and 100 U/ml penicillin-streptomycin in both cases.
|
| Growth protocol |
Treatment with CM272 inhibitor at 400nM during 48hours. Control cells were treated with the correspondig vehicle alone (0.1% DMSO) during 48 hours.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA from cell lines was extracted using the automated Maxwell system from Promega (Madison, WI, USA) according to the manufacturer's instructions.
|
| Label |
biotin
|
| Label protocol |
The sense cDNA was prepared from 300 ng of total RNA using the Ambion® WT Expression Kit. The sense strand cDNA was then fragmented and biotinylated with the Affymetrix GeneChip® WT Terminal Labeling Kit (PN 900671).
|
| |
|
| Hybridization protocol |
Labeled sense cDNA was hybridized to the Affymetrix HuGene-2_0-st chip according to the the manufacturer protocols and using GeneChip® Hybridization, Wash and Stain Kit.
|
| Scan protocol |
Genechips were scanned with the Affymetrix GeneChip® Scanner 3000.
|
| Description |
HepG2 treated with CM272 400nM during 48h
|
| Data processing |
The data were normalized, independently for each cell line, with Bioconductor software using RMA algorithm.
|
| |
|
| Submission date |
Feb 09, 2018 |
| Last update date |
Feb 09, 2021 |
| Contact name |
Maite G Fernandez-Barrena |
| E-mail(s) |
magarfer@unav.es
|
| Organization name |
CIMA
|
| Street address |
Pio XII 55
|
| City |
Pamplona |
| ZIP/Postal code |
31008 |
| Country |
Spain |
| |
|
| Platform ID |
GPL16686 |
| Series (1) |
| GSE110418 |
Expression data from HepG2 and LX2 cells treated with a dual epigenetic inhibitor of G9A and DNMT1. |
|
